Clinical and immunological features of COVID‐19 in patients with anti‐MDA5 dermatomyositis during the omicron wave in Chongqing, China

Na Wu,Zhiwei Chen,Guanhua Zha,Zhiling Deng,Wenhan Huang,Dachuan Cai,Mingli Peng,Peng Hu,Lin Tang,Hong Ren
DOI: https://doi.org/10.1002/jmv.29493
IF: 20.693
2024-03-06
Journal of Medical Virology
Abstract:Patients with anti‐melanoma differentiation‐associated gene 5 (anti‐MDA5) dermatomyositis (DM) have a higher risk of coronavirus disease 2019 (COVID‐19) infection. In this longitudinal observational study, we aimed to investigate the clinical and immunological features of these patients after COVID‐19 infection. A total of 73 patients with anti‐MDA5 DM were recruited from the Second Affiliated Hospital of Chongqing Medical University during the Omicron wave epidemic. Clinical data were collected by questionnaire survey and electronic medical records. Blood samples were used to determine the immunity responses. From December 9, 2022 to March 31, 2023, 67 patients were eligible for final analysis; 68.7% of them were infected with COVID‐19. The most common symptoms observed in COVID‐19 were upper respiratory symptoms, most cases were mild or moderate (97.8%). The clinical laboratory indexes were relativity stable in patients after infection (all p > 0.05). Vaccination is not a protective factor against the Omicron infection (odds ratio: 2.69, 95% confidence interval: 0.81–8.93, p = 0.105). Both wildtype (WT) neutralizing antibodies titer and BA.5‐specific immunoglobulin G titer were significantly enhanced after infection (all p 0.05). However, both the WT‐specific CD8+ T cells and CD4+ T cells were reduced in patients with anti‐MDA5 DM (all p
virology
What problem does this paper attempt to address?